

**List of insider information under Art. 7 of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April 2014 regarding market abuse (Regulation on market abuse) on the circumstances that occurred during the past 9 months**

**Dated 11 January 2019**

**NOTIFICATION**

Sopharma AD notifies that for December 2018 the Company recorded an increase of sales revenues of 26% compared to the same month of 2017, including 75% increase of domestic sales and a decrease of 1% of export sales.

In 2018 revenue from sales of goods decreased by 3% compared to the same period in 2017, incl. 3% increase in sales for the domestic market and 7% decrease in export sales.

„It's been a year of review - on our 85th anniversary, we looked back to enjoy our successes, to thank the people with whom we've achieved them and celebrate with everyone we want to share our future with. Thank you for sharing! We are proud to have been among the pioneers with two major initiatives - we have distributed shares to all our employees according to their length of service and contribution to the company's successes and distributed the first interim dividend. We have received support from our shareholders for both initiatives, which has always been an important indication for us confirming that we are doing the right thing.“, commented Mr. Ognian Donev, PhD, Executive Director and Chairman of the Board of Directors of Sopharma AD.

**Dated 30 January 2019**

**NOTIFICATION**

Sopharma AD received a notification for disclosure of a shareholding under Art. 145 of the CUPF Allianz Bulgaria for acquiring shares from the capital of Sopharma AD, as a result of which the shareholding of CUPF Allianz Bulgaria in the capital of Sopharma AD exceeds the limit of 5% and reaches 5.09%.

The date of the registration of the transaction with the Central Depository is 23 January 2019.

**Dated 30 January 2019**

**NOTIFICATION**

Publishing of the individual quarterly report for the fourth quarter of 2018 of Sopharma AD.

**Dated 5 February 2019**

**NOTIFICATION**

Sopharma AD notifies that for January 2019 the Company recorded an increase of sales revenues of 1% compared to the same month of 2018, including 15% decrease of domestic sales and an increase of 13% of export sales.

**Dated 1 March 2019**

**NOTIFICATION**

Publishing of the quarterly consolidated statement for the fourth quarter of 2017 of Sopharma Group.

**Dated 6 March 2019**

**NOTIFICATION**

Sopharma AD notifies that for February 2019 the Company recorded a decrease of sales revenues of 14% compared to the same month of 2018, including 38% decrease of domestic sales and an increase of 1% of export sales.

During the first two months of 2019 the revenues from sales of production increased by 1% compared to the same period of 2018, including 15% decrease in domestic sales and 13% increase of export sales.

**Dated 29 March 2019**

**NOTIFICATION**

Publishing of the Annual Individual Report of Sopharma AD as at 31.12.2018.

**Dated 5 April 2019**

**NOTIFICATION**

Sopharma AD notifies that for March 2019 the Company recorded an increase of sales revenues of 16% compared to the same month of 2018, including 11% increase of domestic sales and an increase of 22% of export sales.

In the first quarter of 2019 the revenues from sales of production decreased by 2% compared to the first quarter of 2018, including 18% decrease in domestic sales and 11% increase of export sales.

**Dated 25 April 2019**

**NOTIFICATION**

Publishing of an invitation and materials for convening an AGMS of Sopharma AD on 07.06.2019.

**Dated 7 May 2019**

### **NOTIFICATION**

Sopharma AD notifies that for April 2019 the Company recorded a decrease of sales revenues of 7% compared to the same month of 2018, incl. keeping the sales for the domestic market and a decrease of 11% of export sales.

In the first four months of 2019 the revenues from sales of production decreased by 3% compared to the same period of 2018, including 15% decrease in domestic sales and 5% increase of export sales.

**Dated 7 May 2019**

### **NOTIFICATION**

Sopharma AD notifies that for May 2019 the Company recorded an increase in sales of 22% compared to the same month of 2018, incl. 1% increase in sales for the domestic market and 36% growth in export sales.

In the first five months of 2019 the revenues from sales of production increased by 1% compared to the same period of 2018, incl. 13% decrease in domestic sales and 11% increase of export sales.

**Dated 14 June 2019**

### **NOTIFICATION**

Sopharma AD (the "Company") announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
11.06.2019	Buy	15	3,4400
11.06.2019	Buy	4 800	3,4900
11.06.2019	Buy	200	3,4900
11.06.2019	Buy	5 000	3,4800
11.06.2019	Buy	200	3,4900
11.06.2019	Buy	2 000	3,4900
11.06.2019	Buy	3 000	3,4900
11.06.2019	Buy	1 000	3,4800
11.06.2019	Buy	2 000	3,4800
11.06.2019	Buy	1 000	3,4800
11.06.2019	Buy	400	3,4800
11.06.2019	Buy	600	3,4800

**Dated 14 June 2019**

### **NOTIFICATION**

Sopharma AD (the Company) announces that it was notified by Donev Investments Holding AD related to Ognian Ivanov Donev, that Donev Investments Holding AD executed the following transactions related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
11.06.2019	Buy	4800	3,490
11.06.2019	Buy	200	3,490
11.06.2019	Buy	2000	3,490
11.06.2019	Buy	3000	3,490
11.06.2019	Buy	1000	3,480
11.06.2019	Buy	2000	3,480
11.06.2019	Buy	1000	3,480
11.06.2019	Buy	400	3,480
11.06.2019	Buy	600	3,480

**Dated 14 June 2019**

### **NOTIFICATION**

Sopharma AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transaction related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
12.06.2019	Buy	115	3,4400
12.06.2019	Buy	100	3,4400
12.06.2019	Buy	28	3,4400
12.06.2019	Buy	197	3,4700
12.06.2019	Buy	90	3,4400
12.06.2019	Buy	100	3,4600
12.06.2019	Buy	126	3,4400
12.06.2019	Buy	26	3,4400
12.06.2019	Buy	73	3,4300
12.06.2019	Buy	4	3,4300
12.06.2019	Buy	500	3,4300
12.06.2019	Buy	400	3,4300
12.06.2019	Buy	23	3,4300

**Dated 14 June 2019**

**NOTIFICATION**

Sopharma AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
13.06.2019	Buy	130	3,4000
13.06.2019	Buy	100	3,4000

**Dated 17 June 2019**

**NOTIFICATION**

Sopharma AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
14.06.2019	Buy	507	3,4000
14.06.2019	Buy	1 263	3,4000

**Dated 17 June 2019**

**NOTIFICATION**

Sopharma AD (the Company) announces that it was notified by Donev Investments Holding AD related to Ognian Ivanov Donev, that Donev Investments Holding AD executed the following transactions related to shares in the Company:

<b>Date the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
14.06.2019	Buy	100	3,400

**Dated 19 June 2019**

**NOTIFICATION**

Sopharma AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
17.06.2019	Buy	100	3,4000
17.06.2019	Buy	500	3,4000
17.06.2019	Buy	150	3,4100
17.06.2019	Buy	800	3,4100

**Dated 19 June 2019**

**NOTIFICATION**

Sopharma AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
18.06.2019	Buy	50	3,4100
18.06.2019	Buy	600	3,4000
18.06.2019	Buy	42	3,4100
18.06.2019	Buy	150	3,3900

**Dated 20 June 2019**

**NOTIFICATION**

Sopharma AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
19.06.2019	Buy	800	3,3900

19.06.2019	Buy	50	3,3900
19.06.2019	Buy	100	3,3800
19.06.2019	Buy	100	3,3800
19.06.2019	Buy	400	3,4000

#### Dated 24 June 2019

Sopharma AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transaction related to shares in the Company:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
21.06.2019	Buy	50	3,4100

#### Dated 26 June 2019

#### NOTIFICATION

Sopharma AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
25.06.2019	Buy	100	3,3900
25.06.2019	Buy	900	3,3900

#### Dated 27 June 2019

#### NOTIFICATION

Sopharma AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

Date of the transaction	Operation	Number of shares	Unit price (BGN)
26.06.2019	Buy	1 260	3,3600
26.06.2019	Buy	740	3,4000

26.06.2019	Buy	1 260	3,4000
26.06.2019	Buy	710	3,4000
26.06.2019	Buy	30	3,4000
26.06.2019	Buy	1 638	3,4000
26.06.2019	Buy	362	3,4000
26.06.2019	Buy	338	3,4000
26.06.2019	Buy	1 662	3,4000
26.06.2019	Buy	338	3,4000
26.06.2019	Buy	2 000	3,4000
26.06.2019	Buy	162	3,4000
26.06.2019	Buy	2 500	3,4000
26.06.2019	Buy	338	3,4000
26.06.2019	Buy	213	3,4000
26.06.2019	Buy	210	3,4000
26.06.2019	Buy	204	3,4000
26.06.2019	Buy	35	3,4000
26.06.2019	Buy	2 173	3,4000
26.06.2019	Buy	2 000	3,3600
26.06.2019	Buy	150	3,3500

**Dated 27 June 2019**

#### NOTIFICATION

Sopharma AD (the Company) announces that it was notified by Donev Investments Holding AD related to Ognian Ivanov Donev, that Donev Investments Holding AD executed the following transaction related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
26.06.2019	Sell	250	3,380
26.06.2019	Sell	2000	3,360

**Dated 28 June 2019**

#### NOTIFICATION

Sopharma AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
--------------------------------	------------------	-------------------------	-------------------------

27.06.2019	Buy	1 343	3,4200
27.06.2019	Buy	234	3,4200
27.06.2019	Buy	1 670	3,4000
27.06.2019	Buy	200	3,4000

**Dated 1 July 2019**

### **NOTIFICATION**

Sopharma AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
28.06.2019	Buy	200	3,4000

**Dated 5 July 2019**

### **NOTIFICATION**

Sopharma AD notifies that for June 2019 the Company recorded an increase in sales of 1% compared to the same month of 2018, incl. 6% decrease in sales for the domestic market and 7% growth in export sales.

In the first six months of 2019 the revenues from sales of production increased by 1% compared to the same period of 2018, incl. 11% decrease in domestic sales and 10% increase of export sales.

**Dated 30 July 2019**

### **NOTIFICATION**

Sopharma AD notifies that the Company completes H1 2019 with 10% increase of sales revenues from export markets and the main markets continue the tendency for stable growth and good performance of priority products.

Following its strategy for market diversification the company realized sales in Sweden for the first time.

“We strive to stabilize our positions on markets where we entered in the last few years and grow continuously, even though from a low base. Our aim is to diversify and build sustainable partnerships in countries like Vietnam, Tunis, Finland, etc.”, comments Mr. Ognian Donev, PhD, Executive Director and Chairman of the Board of Directors of Sopharma AD.

**Dated 5 August 2019**

**NOTIFICATION**

Sopharma AD notifies that for July 2019 the Company recorded a decrease in sales of 11% compared to the same month of 2018, incl. 3% decrease in sales for the domestic market and 16% decrease in export sales.

In the first seven months of 2019 the revenues from sales of production decreased by 1% compared to the same period of 2018, incl. 10% decrease in domestic sales and 5% increase of export sales.

**Dated 3 September 2019**

**NOTIFICATION**

Sopharma AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
02.09.2019	Buy	46	3,2600

**Dated 4 September 2019**

**NOTIFICATION**

Sopharma AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
03.09.2019	Buy	554	3,2600
03.09.2019	Buy	300	3,3200
03.09.2019	Buy	100	3,2600

**Dated 5 September 2019**

**NOTIFICATION**

Sopharma AD (the “Company”) announces that it was notified by *Mr Ognian Donev, Chairman of the Board of Directors* that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
04.09.2019	Buy	25	3,2600
04.09.2019	Buy	537	3,3400

**Dated 5 September 2019**

### **NOTIFICATION**

Sopharma AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
05.09.2019	Buy	670	3,3400
05.09.2019	Buy	4 850	3,3500
05.09.2019	Buy	500	3,3500

**Dated 5 September 2019**

### **NOTIFICATION**

Sopharma AD notifies that for August 2019 the Company recorded a decrease in sales of 3% compared to the same month of 2018, incl. 2% decrease in sales for the domestic market and 3% decrease in export sales.

In the first eight months of 2019 the revenues from sales of production decreased by 1% compared to the same period of 2018, incl. 9% decrease in domestic sales and 4% increase of export sales.

**Dated 10 September 2019**

### **NOTIFICATION**

Sopharma AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
09.09.2019	Buy	500	3,3400

**Dated 11 September 2019**

**NOTIFICATION**

Sopharma AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
10.09.2019	Buy	480	3,3400
10.09.2019	Sell	3 120	3,3600
10.09.2019	Sell	500	3,3700

**Dated 12 September 2019**

**NOTIFICATION**

Sopharma AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
11.09.2019	Buy	2 000	3,3500
11.09.2019	Buy	1 000	3,3500
11.09.2019	Buy	620	3,3500
11.09.2019	Buy	2 000	3,3700

**Dated 12 September 2019**

**NOTIFICATION**

Sopharma AD announces that it was notified by Donev Investments Holding AD related to Ognian Ivanov Donev, that Donev Investments Holding AD executed the following transaction related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
11.09.2019	Buy	300	3,35
11.09.2019	Buy	173	3,35
11.09.2019	Buy	250	3,36

**Dated 16 September 2019**

**NOTIFICATION**

Sopharma AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
13.09.2019	Buy	74	3,3500
13.09.2019	Buy	2 500	3,4000
13.09.2019	Buy	1 500	3,4000

**Dated 17 September 2019**

**NOTIFICATION**

Sopharma AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
16.09.2019	Buy	500	3,4200
16.09.2019	Buy	19	3,3800
16.09.2019	Buy	309	3,4200
16.09.2019	Buy	98	3,4200
16.09.2019	Buy	100	3,4000
16.09.2019	Buy	900	3,4000
16.09.2019	Buy	750	3,4000
16.09.2019	Buy	250	3,4000

**Dated 18 September 2019**

**NOTIFICATION**

Sopharma AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
--------------------------------	------------------	-------------------------	-------------------------

17.09.2019	Buy	999	3,4000
17.09.2019	Buy	550	3,4300
17.09.2019	Buy	200	3,4300
17.09.2019	Buy	800	3,4200
17.09.2019	Buy	900	3,4300

**Dated 19 September 2019**

### NOTIFICATION

Sopharma AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
18.09.2019	Buy	100	3,4200
18.09.2019	Buy	100	3,4200
18.09.2019	Buy	51	3,4200
18.09.2019	Buy	99	3,4200
18.09.2019	Buy	750	3,4200
18.09.2019	Buy	469	3,4000

**Dated 20 September 2019**

### NOTIFICATION

Sopharma AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
19.09.2019	Buy	500	3,3800
19.09.2019	Buy	250	3,3600
19.09.2019	Buy	117	3,3700

**Dated 25 September 2019**

### NOTIFICATION

Sopharma AD announces that it was notified by Donev Investments Holding AD related to Ognian Ivanov Donev, that Donev Investments Holding AD executed the following transaction related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
20.09.2019	Sell	200	3,420

**Dated 25 September 2019**

### **NOTIFICATION**

Sopharma AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
24.09.2019	Buy	115	3,4600
24.09.2019	Buy	71	3,4000
24.09.2019	Buy	500	3,4000
24.09.2019	Buy	290	3,4500
24.09.2019	Buy	70	3,4500

**Dated 26 September 2019**

### **NOTIFICATION**

Sopharma AD (the “Company”) announces that it was notified by Mr Ognian Donev, Chairman of the Board of Directors that he, executed the following transactions related to shares in the Company:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
25.09.2019	Buy	290	3,4500
25.09.2019	Buy	259	3,4500
25.09.2019	Buy	2 000	3,4600
25.09.2019	Buy	750	3,4000
25.09.2019	Buy	4 000	3,4400
25.09.2019	Buy	4 000	3,4400
25.09.2019	Buy	4 000	3,4400
25.09.2019	Buy	4 000	3,4400
25.09.2019	Buy	2 000	3,4400
25.09.2019	Buy	400	3,4400

**Dated 27 September 2019**

### **NOTIFICATION**

Sopharma AD (the “Company”) announces that pursuant to art. 3, para 1, item 26, letter “a” and art. 19, para 1, letter “a” from Regulation 596/2014 of the European Parliament and of the Council, it was notified by Mrs. Rositsa Doneva, a person closely associated with Mr. Ognian Donev, Chairman of the Board of Directors of Sopharma AD, that she executed the following transactions related to shares of the Sopharma AD:

<b>Date of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
25.09.2019	Buy	500	3,4400

**Dated 27 September 2019**

### **TREASURY SHARES**

Sopharma AD notifies that on September 26, 2019 the Company bought 182 own shares representing 0.0001% of the share capital of the Company, at a total value of 607.88 BGN on the Bulgarian Stock Exchange, the average price per share was 3.34 BGN.

The trading of treasury shares is pursuant to decision by the Extraordinary General Meeting of Shareholders from February 23, 2018.

The total number of treasury shares after this transaction is 8 881 832, representing 6.59% of the share capital of the Company.

**Dated 27 September 2019**

### **NOTIFICATION**

Sopharma AD announces that it was notified by Donev Investments Holding AD related to Ognian Ivanov Donev, that Donev Investments Holding AD executed the following transaction related to shares in the Company:

<b>Date and time of the transaction</b>	<b>Operation</b>	<b>Number of shares</b>	<b>Unit price (BGN)</b>
16.09.2019	Sell	19,00	3,42
16.09.2019	Sell	172,00	3,42
16.09.2019	Sell	500,00	3,42
16.09.2019	Sell	309,00	3,42
16.09.2019	Sell	900,00	3,40